108 related articles for article (PubMed ID: 23732371)
41. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
Reguiai Z; Tabary T; Maizières M; Bernard P
J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
[TBL] [Abstract][Full Text] [Related]
42. [The endocrinological management of thyroid associated orbitopathy in relation to severity and activity of the disease].
Michałek K; Waśko R; Sowiński J
Przegl Lek; 2004; 61(8):838-40. PubMed ID: 15789911
[TBL] [Abstract][Full Text] [Related]
43. [Orbital-bony decompression in patients with dysthyroid orbitopathy--first Croatian experiences].
Juri J; Stiglmayer N; Kuzman T
Acta Med Croatica; 2006; 60(2):83-6. PubMed ID: 16848193
[TBL] [Abstract][Full Text] [Related]
44. [Management of Graves' ophthalmopathy].
Schalin-Jäntti C
Duodecim; 2010; 126(20):2431-7. PubMed ID: 21125757
[TBL] [Abstract][Full Text] [Related]
45. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
Novikov PI; Krivosheev OG; Semenkova EN
Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
[TBL] [Abstract][Full Text] [Related]
46. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
47. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Muller I; Maioli S; Armenti M; Porcaro L; Currò N; Iofrida E; Pignataro L; Manso J; Mian C; Geginat J; Salvi M
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38471303
[TBL] [Abstract][Full Text] [Related]
48. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
50. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
51. [Rituximab for treatment of graves orbitopathy].
Huerva V
Arch Soc Esp Oftalmol; 2011 May; 86(5):162-3. PubMed ID: 21624658
[No Abstract] [Full Text] [Related]
52. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
53. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
54. Interleukin-2 receptor beta and CD57 expression in orbital tissues from patients with chronic, stable thyroid-associated ophthalmopathy.
Rosen CE; Rizzuto PR; Kennerdell JS; Burde RM; Wall JR
Alaska Med; 1994; 36(4):177-82, 207. PubMed ID: 7531401
[TBL] [Abstract][Full Text] [Related]
55. Pulsatile ocular blood flow change after treatment with systemic steroid in patients with Graves' ophthalmopathy.
Tsai CC; Kau HC; Tsai HH; Kao SC; Hsu WM
Eye (Lond); 2006 Sep; 20(9):1025-9. PubMed ID: 16123781
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
57. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
58. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.
Stan MN; Salvi M
Eur J Endocrinol; 2017 Feb; 176(2):R101-R109. PubMed ID: 27760790
[TBL] [Abstract][Full Text] [Related]
59. Low dose orbital radiotherapy for thyroid eye disease.
Li Yim JF; Sandinha T; Kerr JM; Ritchie D; Kemp EG
Orbit; 2011 Dec; 30(6):269-74. PubMed ID: 22132844
[TBL] [Abstract][Full Text] [Related]
60. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.
Wang C; Ning Q; Jin K; Xie J; Ye J
BMC Ophthalmol; 2018 Feb; 18(1):46. PubMed ID: 29452583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
